This pattern was consistent across all three studied tumor models, although the percentage of expression of CD32a and CD16 appeared lower on innate effector cells in B16 tumors relative to the more immunogenic MC38 and MCA205 models (Figure S2B). The gene discussed is FCGR3A; the disease is neoplasm.